Нoxxon to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
NOXXON Pharma will disclose promising data from two independent clinical Phase IIa studies of the anti-CXCL12/SDF-1 Spie…
NOXXON Pharma announced today the publication of a new study in Cell Reports, entitled "SDF-1 Inhibition Targets the Bon…
NOXXON Pharma announced today that one of its Spiegelmer® therapeutics, olaptesed pegol (NOX-A12), received orphan drug…
NOXXON Pharma presented updated interim data sets from two independent clinical Phase IIa studies of the anti-CXCL12/SDF…
NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer…
NOXXON Pharma stellte auf der 55. Jahrestagung der American Society of Hematology (ASH) in New Orleans vom 7.-10. Dezemb…
NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa c…
NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in…
NOXXON Pharma AG, ein biopharmazeutisches Unternehmen und Pionier bei der Entwicklung der eigenen, patentierten neuen Wi…